| gap-pubmed-20260411- | What determines which RCD pathway predominates in different MS disease stages? | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do distinct RCD pathways interact when co-occurring within MS lesions? | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What accounts for structural MRI's low sensitivity in early dementia despite its | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neuroimaging |
| gap-pubmed-20260411- | What is the clinical utility and diagnostic accuracy of emerging synaptic PET tr | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neuroimaging |
| gap-pubmed-20260411- | Why do validated PET tracers for α-synuclein and TDP-43 remain elusive despite o | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neuroimaging |
| gap-pubmed-20260411- | How do therapeutic agents targeting VAPB-PTPIP51 achieve selectivity without dis | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the specific molecular mechanisms by which VAPB-PTPIP51 tether disrupti | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines the temporal dynamics and sustainability of mGluR-mediated rescu | resolved | 0.81 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | Do mGluR-mediated compensatory mechanisms exist in human APOE4 carriers and affe | resolved | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does mGluR-mTORC1 signaling bypass APOE4-induced calcium-mediated translatio | resolved | 0.84 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | How does apoJ modulate Aβ transport across the blood-brain barrier at the molecu | resolved | 0.81 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Which of the four proposed neuroprotective mechanisms of apoJ is most critical i | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why is apoJ rarely present in NFT-containing neurons despite being upregulated i | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms drive differential GLI1 vs c-MYC inhibition patterns in differen | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neuro-oncology |
| gap-pubmed-20260411- | Why does JQ1 show 10-fold differential sensitivity between HD-MB03 and DAOY cell | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuro-oncology |
| gap-pubmed-20260411- | How do differential MMP expression patterns between microglia and myeloid cells | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What mechanisms drive the temporal shift in cytokine expression patterns between | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | Why do microglia remain immunosuppressed while myeloid infiltrates become highly | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the specific molecular mechanisms by which Plk1 regulates spindle check | open | 0.72 | 0.00 | 2026-04-11 | 0 | | cell-cycle-biology |
| gap-pubmed-20260411- | How does Plk1 dysregulation contribute to neurodegeneration through mitotic chec | open | 0.73 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the specific molecular mechanisms linking liver failure to neuropsychia | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do multiple pathological mechanisms (ammonia, manganese, autophagy, mitochon | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines disease-specific patterns of BBB disruption across different neu | resolved | 0.81 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do Wnt/β-catenin and VEGF pathways interact to regulate BBB integrity in neu | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Which of the 253 core DSS ingredients are necessary and sufficient for GSK3β/PGC | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does DSS achieve therapeutic effects through energy metabolism when Aβ-targe | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Can therapeutic efficacy in genetic CJD be achieved without reducing pathologica | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms link sulfated glycosaminoglycan accumulation to prion disease pa | resolved | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does Metformin fail to delay CJD progression despite improving anti-aging ha | partially_addressed | 0.89 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do BIN1 variants interact with APOE ε4 to modulate LOAD risk in different po | resolved | 0.81 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What is the functional mechanism by which BIN1 P318L missense mutation increases | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do different BIN1 variants confer LOAD risk in Han Chinese versus European p | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Do other RNA-binding proteins regulate firing pattern plasticity in cholinergic | open | 0.76 | 0.00 | 2026-04-11 | 0 | | post-transcriptional-regulation |
| gap-pubmed-20260411- | How does nicotine withdrawal specifically downregulate Pum1 expression in MHbChA | open | 0.85 | 0.00 | 2026-04-11 | 0 | | addiction-neurobiology |
| gap-pubmed-20260411- | What determines the baseline heterogeneity of Pum1+/- subpopulations in MHbChAT | open | 0.80 | 0.00 | 2026-04-11 | 0 | | cholinergic-neurobiology |
| gap-pubmed-20260411- | How do alterations in ER-mitochondria tethering causally contribute to neurodege | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the specific molecular mechanisms by which PINK1/Parkin modulate Ca2+ s | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What alternative acoustic frequency ranges or detection methods could identify α | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do α-synuclein fibrils lack detectable ultrasound signatures despite their d | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does transient GABA interneuron inhibition produce sustained antidepressant | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neuropsychiatry |
| gap-pubmed-20260411- | Do Sst+ and Pvalb+ interneuron subtypes contribute equally to antidepressant eff | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuropsychiatry |
| gap-pubmed-20260411- | What molecular mechanisms link GABA interneuron inhibition to enhanced synaptic | open | 0.80 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | How do TREM2 ligand interactions regulate microglial plaque envelopment and main | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the molecular mechanisms by which TREM2 variants increase AD risk? | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What upstream signals cause PCGF1 downregulation in microglia during adolescent | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | Why is PCGF1 specifically decreased in adolescent depression compared to adult d | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does PCGF1 coordinate dual histone modifications (H2AK119ub and H3K27me3) to | resolved | 0.84 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How do compartment-specific origins (CBM vs FBM vs PBMCs) influence the function | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the functional roles and mechanisms of action of the novel CD14+ myeloi | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-debate-20260411- | What receptor tyrosine kinase signaling changes drive early synaptic pathology i | open | 0.75 | 0.70 | 2026-04-11 | 0 | | neurodegeneration |